AstraZeneca Sees SOURCE Tezepelumab Failure In Asthma
Comes After Delay For Roxadustat In The US
The SOURCE failure is a reversal for the novel Amgen-partnered TSLP inhibitor after NAVIGATOR success last month, and comes just days after the US FDA requested more analyses of the pivotal data for the kidney disease anemia therapy roxadustat.
You may also be interested in...
Tezspire All Set To Tackle Big Biologic Rivals In Severe Asthma
With a European approval in the bag for Tezspire, AstraZeneca is looking for quick and successful launches of the severe asthma drug so it can mount a challenge to the other biologics in the space, notably Sanofi and Regeneron’s Dupixent.
Amgen Expects Quick, Broad Adoption Of Tezspire In Severe Asthma
Company says new asthma drug partnered with AstraZeneca will offer a new therapy option for severe patients with low eosinophil counts. The firms will provide launch plans in January.
Amgen And AstraZeneca Tout Fresh Tezepelumab Data
Recently-submitted tezepelumab reduced the annualized asthma exacerbation rate by 86% in a subgroup of patients with severe, uncontrolled asthma and nasal polyps, according to data presented at the European Respiratory Society congress.